Arteris, Inc. SEC Filings

Arteris, Inc. insider filing reports that Bayview Legacy, LLC, an entity managed by K. Charles Janac, sold 100,000 shares of Arteris common stock on 10/06/2025 under a 10b5-1 trading plan. The sales were executed in multiple transactions at weighted-average price $13.1045, with trade prices ranging from $12.50 to $13.85. After the disposition, Bayview Legacy, LLC is reported to beneficially own 9,739,071 shares, and Janac is deemed to have voting and dispositive power as the manager. Janac also filed a separate Form 4 reporting the same sale in his individual capacity.

Arteris, Inc. director Antonio J. Viana reported insider sales on 10/06/2025. The filing shows a sale of 11,841 shares of common stock at a price of $14 and an additional disposal of 20,840 common shares. After these transactions the reporting person is listed as beneficially owning 184,620 shares indirectly through the Viana Family Trust. The sales were made under a pre-existing Rule 10b5-1 trading plan that the reporting person adopted on 06/10/2025, and the Form 4 was signed by an attorney-in-fact on 10/06/2025. The filing presents routine, planned insider disposals rather than unscheduled or ad-hoc trades.

Arteris, Inc. (AIP) submitted a Rule 144 notice proposing the sale of 50,000 common shares through Morgan Stanley Smith Barney LLC for an aggregate market value of $647,500. The notice lists the company's total outstanding shares as 42,649,917 and an approximate sale date of 10/08/2025. The shares were originally acquired from the issuer in a private transaction on 11/05/2013 and were paid for in cash. The filing also discloses multiple recent sales by related parties and 10b5-1 plans in the past three months, including transactions dated 08/05/2025, 09/02/2025, and 10/06/2025, with amounts ranging up to $1,310,450.00 in gross proceeds for a single sale.

Arteris, Inc. filing a Form 144 notifies a proposed sale of 6,421 common shares (acquired as restricted stock units) with an aggregate market value of $87,197.18, through Morgan Stanley Smith Barney LLC on or about 10/07/2025. The RSUs were recorded as acquired on 10/01/2025 and the filing lists previous sales by the same person totaling 30,538 shares during the prior three months, generating gross proceeds of $336,546.61. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 sales plans used for several prior transactions.

Insider sale summary: A Form 4 shows that Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), sold a total of 7,627 shares of common stock in two days, 10/02/2025 and 10/03/2025, to satisfy tax obligations arising from the release of restricted stock units and under a previously adopted trading plan. The reported weighted average sale prices ranged from $10.81 to $11.30 with the weighted averages disclosed as $10.9208 and $11.082.

After these dispositions, the reporting person beneficially owned 65,960 shares directly. One tranche of the sales was executed pursuant to a 10b5-1 trading plan adopted on 06/05/2025, and the filer states the sales served to cover tax liabilities from released restricted stock units.

Arteris, Inc. (AIP) reported insider transactions by its Chief Operating Officer. On 10/02/2025, the COO sold 1,885, 891, and 1,926 shares at $10.9208 per share, including shares sold to satisfy tax liabilities from restricted stock unit release. Additional sales under a Rule 10b5-1 trading plan adopted on March 12, 2025 included 19,060 shares at a weighted average price of $10.9908 on 10/02/2025, 1,554 shares at $11.0866 on 10/03/2025, and 17,200 shares at $12.6598 on 10/06/2025.

Following these transactions, the COO beneficially owned 343,885 shares directly.

Arteris (AIP) — Form 4 insider activity: President and CEO K. Charles Janac, who is also a Director and 10% Owner, reported open‑market sales on 10/02/2025 and 10/03/2025. The filing lists sales of 2,767, 1,613, and 2,767 shares at $10.9208, and a separate sale of 11,821 shares at a weighted average price of $11.0705 (with individual trades between $10.80 and $11.29).

One set of shares was sold to satisfy the reporting person’s tax liability from an RSU release, and another transaction was made under a Rule 10b5‑1 trading plan adopted on March 5, 2025. Following the reported transactions, direct holdings were shown as 167,514 shares. Indirect holdings were listed as 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares held by the Charles and Lydia Janac Trust.

Insider sale to cover taxes by Arteris CFO. On 10/02/2025, Nicholas B. Hawkins, the company’s Vice President and Chief Financial Officer, reported three open-market sales of 3,887 shares of Arteris, Inc. (AIP) at an effective price of $10.9208 per share. The three disposals were for 891, 1,508 and 1,488 shares and reduced the reporting person’s direct holdings in stages from 103,007 shares to 100,011 shares following the transactions.

The filing states the shares were sold to satisfy the reporting person’s tax liability triggered by the release of restricted stock units. The Form 4 was signed by an attorney-in-fact on 10/06/2025. No derivative transactions or other types of securities were reported.

Arteris, Inc. director Joachim Kunkel reported receipt of 1,496 shares of common stock as fully vested restricted stock on 10/05/2025. The shares were issued as retainer fees elected in lieu of cash and the reporting person elected to defer receipt; the transaction price is reported as $0.00.

Following the transaction, the reporting person beneficially owns 67,818 shares. The Form 4 was signed by an attorney-in-fact on 10/06/2025 and indicates the filing is by one reporting person and that the reporting person is a director.